Next-Generation Sequencing Market to Reach USD 29.54 Billion by 2032, Growing at a CAGR of 14.94% During 2026–2032

The next-generation sequencing market was valued at USD 12.02 billion in 2025 and is projected to grow from USD 12.81 billion in 2026 to USD 29.54 billion by 2032, registering a CAGR of 14.94% during the forecast period. Market expansion is being driven by the increasing global burden of cancer, rare genetic disorders, and infectious diseases, which continue to accelerate the adoption of genomic profiling, molecular diagnostics, and precision medicine applications across healthcare worldwide.

Growing institutional investments in cancer genomics and public health sequencing infrastructure are further supporting industry expansion. According to the World Health Organization’s International Agency for Research on Cancer (IARC), global cancer cases reached approximately 20 million, with the figure projected to rise substantially over the coming decades. Regulatory approvals and precision medicine initiatives are also accelerating clinical adoption of next-generation sequencing technologies.

In 2024, Illumina received FDA approval for TruSight Oncology Comprehensive, the first FDA-approved distributable comprehensive genomic profiling in vitro diagnostic kit with pan-cancer companion diagnostic claims. Such regulatory developments are enabling healthcare providers and oncology laboratories to integrate sequencing-based diagnostics into routine clinical workflows, thereby strengthening recurring demand for sequencing platforms, flow cells, consumables, and bioinformatics services globally.

Furthermore, the rising integration of artificial intelligence into genomic data analysis is transforming sequencing workflows and expanding accessibility across decentralized laboratories and community hospitals. Strategic collaborations between Illumina and NVIDIA in 2025 enhanced GPU-accelerated genomic analysis capabilities through the DRAGEN bioinformatics platform and Illumina Connected Analytics ecosystem. Additionally, increasing investments in cloud-based bioinformatics platforms, single-cell genomics, and AI-enabled sequencing analytics are creating substantial opportunities for market participants operating across clinical genomics, pharmaceutical research, and precision oncology applications.

North America accounted for the leading market share of approximately 42% due to advanced genomic infrastructure, strong biotechnology manufacturing capacity, and sustained public investment in life sciences research. Government-backed initiatives across the United States and Canada continue strengthening sequencing infrastructure, precision medicine adoption, and genomic data generation capabilities. Moreover, the region hosts a high concentration of pharmaceutical companies, genomic research institutes, and clinical laboratories, further supporting continuous demand for next-generation sequencing technologies and bioinformatics solutions, as stated in the recent report “Next-Generation Sequencing Market Analysis, 2026”.

Next-Generation Sequencing Market Highlights

The global next-generation sequencing market was valued at USD 12.02 billion in 2025 and is projected to grow from USD 12.81 billion in 2026 to USD 29.54 billion by 2032, exhibiting a CAGR of 14.94% during 2026–2032.
North America leads all regions with approximately 42% share of the next-generation sequencing globally.
Within the type of offering dimension, consumables account for approximately 52% share, driven by the recurring per-run procurement of reagents, library preparation kits, flow cells, and consumable kits across clinical and research laboratories globally.
Sequencing by synthesis dominates the technology dimension with approximately 75% share, reflecting its established position as the accuracy and throughput standard across whole-genome sequencing, targeted panel testing, and clinical diagnostics applications.
The global next-generation sequencing market industry is moderately consolidated, with a limited number of multinational genomics and life sciences companies collectively accounting for approximately 50% share.

Next-Generation Sequencing Market Segmentation

By Type of Offering

Products
- Instruments
  - NGS sequencers
  - Automation systems
- Consumables
  - Reagents
  - Library prep kits
  - Flow Cells and Chips
  - Consumable Kits
Services
- Sequencing services
- Bioinformatics and data analysis services
- Contract research and consulting services

By Technology

Sequencing by synthesis
Ion semiconductor sequencing
Single molecule real time sequencing
Nanopore sequencing
Others

By Workflow

Sample Preparation
Sequencing
Data Analysis

By Application

Clinical Applications
- Inherited disease diagnostics
- Cancer genomics
- Infectious disease testing
- Reproductive health testing
- Pharmacogenomics
Research and Applied Applications
- Basic genomics and transcriptomics
- Functional genomics and CRISPR screens
- Agriculture and microbiology
- Evolutionary biology and forensics